Department of Biomedical Sciences, College of Medicine, Inha University, Incheon, Korea.
Cancer Sci. 2012 Nov;103(11):1929-37. doi: 10.1111/j.1349-7006.2012.02409.x. Epub 2012 Sep 25.
Identification of small molecules that safely inhibit cancer progression is critical for cancer therapeutics. Saponins exhibit cytostatic and cytotoxic activity against various cancer cells, but the mechanism is not well understood. Here, we investigated whether saponin D (designated SB365), an active component isolated from Pulsatilla koreana, could inhibit the progression of hepatocellular carcinoma (HCC) and considered its mechanism. SB365 strongly suppressed the growth of HCC cells in a dose-dependent manner and induced apoptosis by increasing the proportion of sub G1 apoptotic cells from 8% to 21% through induction of expression of Bax and cleaved caspase-3. In addition, SB365 exhibited potent anti-angiogenic activity and decreased the expression of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor, a key molecule for angiogenesis. Furthermore, SB365 suppressed the tube formation and migration of HUVEC, as well as in vivo neovascularization in a mouse Matrigel plug assay. In vivo study showed that SB365 significantly inhibited tumor growth in an HCC xenograft model, inducing apoptosis by increasing the expression of the cleaved caspase-3 and DNA fragmentation. The expressions of vascular endothelial growth factor and CD34 in the tumor tissue were decreased by SB365 treatment. In examining its mechanism, SB365 was found to effectively suppress the phosphorylation of PI3K downstream factors, such as Akt, mTOR and p70S6K both in vitro and in vivo. Our study demonstrates that SB365 not only induces apoptosis but also inhibits cell growth and angiogenesis through modulation of the PI3K/Akt/mTOR pathway in human HCC. We suggest that SB365 may be a new chemotherapeutic candidate against HCC.
鉴定能够安全抑制癌症进展的小分子化合物对于癌症治疗至关重要。皂苷对各种癌细胞具有细胞生长抑制和细胞毒性作用,但作用机制尚不清楚。在这里,我们研究了源自白头翁的活性成分皂苷 D(命名为 SB365)是否可以抑制肝细胞癌(HCC)的进展,并探讨了其作用机制。SB365 能够强烈抑制 HCC 细胞的生长,呈剂量依赖性,通过诱导 Bax 和 cleaved caspase-3 的表达,将亚 G1 期凋亡细胞的比例从 8%增加到 21%,从而诱导细胞凋亡。此外,SB365 表现出强大的抗血管生成活性,并降低了缺氧诱导因子-1α(HIF-1α)和血管内皮生长因子的表达,血管内皮生长因子是血管生成的关键分子。此外,SB365 抑制了 HUVEC 的管形成和迁移,以及在小鼠 Matrigel plugs 实验中的体内新生血管形成。体内研究表明,SB365 在 HCC 异种移植模型中显著抑制肿瘤生长,通过增加 cleaved caspase-3 和 DNA 片段的表达诱导细胞凋亡。SB365 处理降低了肿瘤组织中血管内皮生长因子和 CD34 的表达。在研究其作用机制时,发现 SB365 能够有效地抑制 PI3K 下游因子如 Akt、mTOR 和 p70S6K 的磷酸化,无论是在体外还是体内。我们的研究表明,SB365 通过调节 PI3K/Akt/mTOR 通路,不仅诱导细胞凋亡,还抑制细胞生长和血管生成,在人类 HCC 中。我们认为 SB365 可能是一种针对 HCC 的新化疗候选药物。